| |FEBRUARY 20268ZYDUS LAUNCHES TISHTHA, WORLD'S FIRST NIVOLUMAB BIOSIMILARMERCK JOINS FORCES TO IMPROVE ACCESS TO EBOLA VACCINE WORLDWIDEMerck, a global leader in pharmaceuticals, has announced a new partnership with a prominent global health coalition to make its life-saving Ebola vaccine more affordable and accessible.They desire to support areas that are most affected by Ebola to have more people against the harmful virus.The strategy is aimed at ensuring that Merck Ebola vaccine, Ervebo is improved. The companies also desire to reduce the price in order to make it accessible to poorer countries at a cheaper cost. Merck will also strive more to deliver the vaccine to the outbreak prone places."We believe this partnership will bring real change to communities affected by Ebola," said Dr Julie L. Gerberding, Executive Vice President of Merck. "By making this vaccine more affordable, we can save lives and stop outbreaks faster."This collaboration comes in handy with the war against Ebola, particularly in nations that lack adequate health care. It demonstrates the commitment of Merck to benefit the whole world by ensuring that those who require the protection most do not lag behind. The work would prevent future outbreaks and reduce the horrible impacts of the disease. POTOP STORIESZydus Lifesciences has introduced the world's first biosimilar of Nivolumab, Tishtha, in India, marking a significant step in improving access to advanced immunotherapy for cancer patients.This revolutionary step will enhance Zydus experience in biologics and immuno-oncology besides addressing the financial and accessibility dilemma affecting several cancer patients.Tishtha has two strengths of 100mcg and 40mcg with 28950 and 13950 respectively. It is priced at a quarter of the reference product, which presents a more cost-effective alternative to patients who undergo long-term cancer therapies. The two-dose dosage can also be used to reduce wastage aiming at streamlining the treatment regimen towards improved cost management.Dr Sharvil P Patel, Managing Director of Zydus Lifesciences, highlighted the fact that the aim of the company is to provide timely and affordable access to cancer treatments. Zydus has a desire to invest in high-quality biosimilars and the initiation of Tishtha signifies its dedication to patient-centred care.Consistency, affordability, and access are the factors that determine the availability of modern cancer treatments. As continuous therapy is very vital and plays a critical role in ensuring the continuity of patients, Tishtha is a major contributor to the oncology treatments in the country since it will guarantee long-term service. It is created and produced in India and assists oncologists and healthcare systems to be able to offer quality care.The introduction of Tishtha by Zydus is a great step in the right direction, towards the provision of immuno-oncology therapies to cancer patients throughout India with improved success. PO
< Page 7 | Page 9 >